Company / Cash per Share
Travere Therapeutics, Inc. Cash per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$1.06
FY2025
5-year range
$0.78 / $3.17
FY2021-FY2025
Trend
+37.0%
vs FY2024
Sector context
#146 of 205
Health Care
What the data says
At $1.06, Travere Therapeutics, Inc.'s cash per share ranks #146 of 205 in the Health Care sector. Cash per Share returned to growth in FY2025 after 3 years of decline, reaching $1.06.
Based on SEC 10-K filings.
1.06 in FY2025 with a 5-year CAGR of -11.6%.
Improved from $0.90 to $1.06 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- +2.5%
- 5-Year CAGR
- -11.6%
- 10-Year CAGR
- -
Sector benchmark
#146 of 205 in Health CareTop 71% of 205This company $1.06 Sector average $72.93
▼
-98.5% below sector average
Key checks
Key Insights
- In FY2025, cash per share increased 37.0% year-over-year.
- Ranks #146 out of 205 companies in the Health Care sector.
- Peak cash per share was recorded in FY2021.
- Lowest cash per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.06 | +37.0% |
| FY2024 | $0.78 | -14.2% |
| FY2023 | $0.90 | -8.3% |
| FY2022 | $0.99 | -68.9% |
| FY2021 | $3.17 | +61.3% |
| FY2020 | $1.97 | +30.4% |
| FY2019 | $1.51 | -42.3% |
| FY2018 | $2.61 | +162.0% |
| FY2017 | $1.00 | +99.8% |
| FY2016 | $0.50 | -65.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026